Literature DB >> 8450061

A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus.

I Z Zador1, G D Deshmukh, R Kunkel, K Johnson, N S Radin, J A Shayman.   

Abstract

Glucosylceramide (GlcCer) and related glycosphingolipids have been implicated as causal elements in both the growth of cells and in the regulation of hormonal signaling. We therefore studied whether the renal hypertrophy induced by diabetes was associated with enhanced synthesis of glycosphingolipids. 16 d after the induction of diabetes, increases in renal size and concentration of glucocerebroside and ganglioside GM3 were observed paralleling an increase in UDP-Glc concentration. GlcCer synthase and beta-glucosidase-specific activities were no different between control and diabetic kidneys. The apparent Km of the GlcCer synthase with respect to UDP-Glc was 250 microM and was unchanged in the diabetic kidneys. The observed concentrations of UDP-Glc were 149 and 237 microM in control and diabetic kidneys, respectively. The UDP-Glc level is thus rate limiting with regard to GlcCer synthesis. To determine whether the changes in glycolipid content were functionally significant, diabetic and control groups were treated with the GlcCer synthase inhibitor, D-threo-1-phenyl-2-decanoyl-amino-3-morpholino-1- propanol, 2 wk after the induction of diabetes. Kidney weights in the diabetic rats treated with D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol were no different than the control groups. Morphometric analysis of glomerular volumes paralleled changes in renal growth. Glycosphingolipid formation may therefore represent a significant pathway for glucose utilization in early diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450061      PMCID: PMC288030          DOI: 10.1172/JCI116299

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

Review 1.  Glycosylation products as toxic mediators of diabetic complications.

Authors:  M Brownlee
Journal:  Annu Rev Med       Date:  1991       Impact factor: 13.739

2.  Preparative isolation of cerebrosides (galactosyl and glucosyl ceramide).

Authors:  N S Radin
Journal:  J Lipid Res       Date:  1976-05       Impact factor: 5.922

3.  Distribution of glucose and related metabolites in rat kidney.

Authors:  P Needleman; J V Passonneau; O H Lowry
Journal:  Am J Physiol       Date:  1968-09

4.  Effect of diabetes on the sugar nucleotides in several tissues of the rat.

Authors:  M J Spiro
Journal:  Diabetologia       Date:  1984-01       Impact factor: 10.122

5.  Regulation of pathways of glucose metabolism in kidney. Specific linking of pentose phosphate pathway activity with kidney growth in experimental diabetes and unilateral nephrectomy.

Authors:  K A Steer; M Sochor; A M Gonzalez; P McLean
Journal:  FEBS Lett       Date:  1982-12-27       Impact factor: 4.124

6.  Development of glomerular lesions in experimental long-term diabetes in the rat.

Authors:  K Hirose; R Osterby; M Nozawa; H J Gundersen
Journal:  Kidney Int       Date:  1982-05       Impact factor: 10.612

7.  (3-sn-Phosphatidyl)cholines (lecithins) in amniotic fluid.

Authors:  J C Touchstone; S S Levin; M F Dobbins; L Matthews; P C Beers; S G Gabbe
Journal:  Clin Chem       Date:  1983-11       Impact factor: 8.327

8.  Effect of alloxan diabetes on kidney growth in intact and castrated mice.

Authors:  P D Broulik; V Schreiber
Journal:  Acta Endocrinol (Copenh)       Date:  1982-01

9.  Alterations in renal cortex cation homeostasis during mercuric chloride and gentamicin nephrotoxicity.

Authors:  J M Weinberg; P G Harding; H D Humes
Journal:  Exp Mol Pathol       Date:  1983-08       Impact factor: 3.362

10.  Effects of early diabetes on uridine diphosphosugar synthesis in the rat renal cortex.

Authors:  P Cortes; F Dumler; K S Sastry; C P Verghese; N W Levin
Journal:  Kidney Int       Date:  1982-05       Impact factor: 10.612

View more
  35 in total

Review 1.  Treating glucosphingolipid disorders by chemotherapy: use of approved drugs and over-the-counter remedies.

Authors:  N S Radin
Journal:  J Inherit Metab Dis       Date:  2000-12       Impact factor: 4.982

2.  Sphingolipids, new kids on the block, promoting glomerular fibrosis in the diabetic kidney.

Authors:  Lisa M Harrison-Bernard
Journal:  Am J Physiol Renal Physiol       Date:  2015-07-08

3.  Lactosylceramide contributes to mitochondrial dysfunction in diabetes.

Authors:  Sergei A Novgorodov; Christopher L Riley; Jin Yu; Jarryd A Keffler; Christopher J Clarke; An O Van Laer; Catalin F Baicu; Michael R Zile; Tatyana I Gudz
Journal:  J Lipid Res       Date:  2016-02-21       Impact factor: 5.922

4.  Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells.

Authors:  Marimuthu Subathra; Midhun Korrapati; Lauren A Howell; John M Arthur; James A Shayman; Rick G Schnellmann; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2015-06-03

5.  Histochemical and immunoelectron microscopic analysis of ganglioside GM3 in human kidney.

Authors:  Tetsuya Kaneko; Yoshiharu Tsubakihara; Hiroaki Fushimi; Seiji Yamaguchi; Yoshitsugu Takabatake; Hiromi Rakugi; Hayato Kawakami; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2014-07-02       Impact factor: 2.801

6.  Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes.

Authors:  Maria F Lopes-Virella; Nathaniel L Baker; Kelly J Hunt; Samar M Hammad; John Arthur; Gabriel Virella; Richard L Klein
Journal:  J Clin Lipidol       Date:  2019-04-03       Impact factor: 4.766

Review 7.  Lipid biology of the podocyte--new perspectives offer new opportunities.

Authors:  Alessia Fornoni; Sandra Merscher; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2014-05-27       Impact factor: 28.314

8.  Glucose availability and glycolytic metabolism dictate glycosphingolipid levels.

Authors:  Morgan Stathem; Subathra Marimuthu; Julie O'Neal; Jeffrey C Rathmell; Jason A Chesney; Levi J Beverly; Leah J Siskind
Journal:  J Cell Biochem       Date:  2015-01       Impact factor: 4.429

Review 9.  Targeting Glycosphingolipid Metabolism to Treat Kidney Disease.

Authors:  James A Shayman
Journal:  Nephron       Date:  2016-03-09       Impact factor: 2.847

10.  Dysregulated sphingolipid metabolism in endometriosis.

Authors:  Yie Hou Lee; Chin Wen Tan; Abhishek Venkatratnam; Chuen Seng Tan; Liang Cui; Seong Feei Loh; Linda Griffith; Steven R Tannenbaum; Jerry Kok Yen Chan
Journal:  J Clin Endocrinol Metab       Date:  2014-06-24       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.